Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CB-012

Cell therapy (CAR-T) · Kills target cells, directed at C-type lectin-like molecule-1 (CLL-1) (CLEC12A) · developed by Caribou Biosciences

Phase 1 Most advanced trial (none active)
CRBU Developer
1 Registered trials

What is CB-012?

CB-012 is an allogeneic, CRISPR-edited off-the-shelf T-cell therapy carrying a chimeric antigen receptor that binds CLL-1 on tumor cells, leading to cytotoxic T-lymphocyte-mediated killing. The cells also have PD-1 knocked out and TRAC deleted to prevent graft-versus-host disease. It is studied in acute myeloid leukemia that is relapsed or refractory.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Cyclophosphamide, Fludarabine
Drug type
Cell therapy (CAR-T)
Targets
C-type lectin-like molecule-1 (CLL-1) (CLEC12A) (antigen), programmed cell death protein 1 (PD-1) (PDCD1) (secondary target)
Mechanism
Kills target cells, directed at C-type lectin-like molecule-1 (CLL-1) (CLEC12A)
Pathways
T-cell exhaustion, tumor immune evasion
Therapy area
Oncology
Developer
Caribou Biosciences, Inc. (CRBU)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06128044 Phase 1 Acute Myeloid Leukemia, in Relapse Terminated CRBU

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse

More from Caribou Biosciences

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CRBU page.

Follow CRBU, the company behind CB-012

See CRBU's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRBU catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.